Importantly, we found that the CTNNB1-enriched subgroup harbored frequent PTEN mutations but not for KRAS mutations, suggesting that PTEN loss but not KRAS mutations might enhance the CTNNB1-induced genetic program to promote tumor development in endometrial cancer (Figure 6A) (Supplementary Table 9). The gene discussed is PTEN; the disease is endometrial cancer.